Adriana Sumoza-Toledo1, Mario Iván Espinoza-Gabriel2, Dvorak Montiel-Condado3. 1. Instituto de Investigaciones Médico-Biológicas, Universidad Veracruzana, Veracruz, Veracruz, Mexico. Electronic address: asumoza@uv.mx. 2. Instituto de Investigaciones Médico-Biológicas, Universidad Veracruzana, Veracruz, Veracruz, Mexico; Facultad de Bioanálisis, Universidad Veracruzana, Veracruz, Veracruz, Mexico. 3. Laboratorio de Ciencias Genómicas, Facultad de Ciencias Biológicas, Universidad Autónoma de Nuevo León, San Nicolás de los Garza, Nuevo León, Mexico.
Abstract
BACKGROUND: Breast cancer is one of the most common malignancies affecting women. Recent investigations have revealed a major role of ion channels in cancer. The transient receptor potential melastatin-2 (TRPM2) is a plasma membrane and lysosomal channel with important roles in cell migration and cell death in immune cells and tumor cells. METHODS: In this study, we investigated the prognostic value of TRPM2 channel in breast cancer, analyzing public databases compiled in Oncomine™ (Thermo Fisher, Ann Arbor, MI) and online Kaplan-Meier Plotter platforms. RESULTS: The results revealed that TRPM2 mRNA overexpression is significant in situ and invasive breast carcinoma compared to normal breast tissue. Furthermore, multi-gene validation using Oncomine™ showed that this channel is coexpressed with proteins related to cellular migration, transformation, and apoptosis. On the other hand, Kaplan-Meier analysis exhibited that low expression of TRPM2 could be used to predict poor outcome in ER- and HER2+ breast carcinoma patients. CONCLUSIONS: TRPM2 is a promising biomarker for aggressiveness of breast cancer, and a potential target for the development of new therapies.
BACKGROUND:Breast cancer is one of the most common malignancies affecting women. Recent investigations have revealed a major role of ion channels in cancer. The transient receptor potential melastatin-2 (TRPM2) is a plasma membrane and lysosomal channel with important roles in cell migration and cell death in immune cells and tumor cells. METHODS: In this study, we investigated the prognostic value of TRPM2 channel in breast cancer, analyzing public databases compiled in Oncomine™ (Thermo Fisher, Ann Arbor, MI) and online Kaplan-Meier Plotter platforms. RESULTS: The results revealed that TRPM2 mRNA overexpression is significant in situ and invasive breast carcinoma compared to normal breast tissue. Furthermore, multi-gene validation using Oncomine™ showed that this channel is coexpressed with proteins related to cellular migration, transformation, and apoptosis. On the other hand, Kaplan-Meier analysis exhibited that low expression of TRPM2 could be used to predict poor outcome in ER- and HER2+ breast carcinomapatients. CONCLUSIONS:TRPM2 is a promising biomarker for aggressiveness of breast cancer, and a potential target for the development of new therapies.
Authors: Paulina Gil-Kulik; Ewa Dudzińska; Elżbieta Radzikowska-Büchner; Joanna Wawer; Mariusz Jojczuk; Adam Nogalski; Genowefa Anna Wawer; Marcin Feldo; Wojciech Kocki; Maria Cioch; Anna Bogucka-Kocka; Mansur Rahnama; Janusz Kocki Journal: BMC Cancer Date: 2020-05-18 Impact factor: 4.430
Authors: Alana L Cutliffe; Sharon L McKenna; Darshan S Chandrashekar; Alvin Ng; Ginny Devonshire; Rebecca C Fitzgerald; Tracey R O'Donovan; John J Mackrill Journal: Explor Target Antitumor Ther Date: 2021-12-31